Neuberger Berman Group LLC Increases Stake in Dexcom (DXCM)

Neuberger Berman Group LLC lifted its holdings in Dexcom (NASDAQ:DXCM) by 501.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 637,416 shares of the medical device company’s stock after acquiring an additional 531,513 shares during the quarter. Neuberger Berman Group LLC’s holdings in Dexcom were worth $47,271,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. American International Group Inc. purchased a new stake in shares of Dexcom in the 4th quarter worth approximately $116,000. Thompson Davis & CO. Inc. purchased a new stake in shares of Dexcom in the 4th quarter worth approximately $137,000. SG Americas Securities LLC purchased a new stake in shares of Dexcom in the 1st quarter worth approximately $175,000. Marco Investment Management LLC purchased a new stake in shares of Dexcom in the 4th quarter worth approximately $201,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of Dexcom in the 4th quarter worth approximately $208,000.

Shares of Dexcom stock opened at $86.91 on Tuesday. The company has a current ratio of 5.83, a quick ratio of 5.42 and a debt-to-equity ratio of 0.79. Dexcom has a 12-month low of $42.62 and a 12-month high of $88.60. The company has a market cap of $7.63 billion, a price-to-earnings ratio of -149.84 and a beta of 0.01.

Dexcom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.32). Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The business had revenue of $184.40 million for the quarter, compared to analyst estimates of $172.66 million. During the same quarter in the prior year, the business posted ($0.49) EPS. Dexcom’s revenue for the quarter was up 29.6% compared to the same quarter last year. research analysts forecast that Dexcom will post -0.52 EPS for the current year.

In other Dexcom news, EVP Richard Doubleday sold 1,638 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $56.32, for a total transaction of $92,252.16. Following the transaction, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,663,559.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $85.90, for a total transaction of $859,000.00. Following the transaction, the insider now owns 511,674 shares in the company, valued at approximately $43,952,796.60. The disclosure for this sale can be found here. Insiders have sold a total of 117,432 shares of company stock worth $9,638,262 in the last 90 days. 1.80% of the stock is currently owned by company insiders.

Several equities research analysts have recently weighed in on the stock. ValuEngine cut shares of Dexcom from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Piper Jaffray Companies set a $78.00 target price on shares of Dexcom and gave the company a “buy” rating in a research report on Friday, March 23rd. BTIG Research reissued a “hold” rating on shares of Dexcom in a research report on Thursday, May 3rd. Zacks Investment Research raised shares of Dexcom from a “sell” rating to a “hold” rating in a research report on Friday, March 16th. Finally, Oppenheimer set a $67.00 target price on shares of Dexcom and gave the company a “buy” rating in a research report on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Dexcom presently has an average rating of “Buy” and an average target price of $69.79.

Dexcom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dexcom (NASDAQ:DXCM).

Institutional Ownership by Quarter for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply